Vaxart (NASDAQ:VXRT) Upgraded by BidaskClub to Hold

Vaxart (NASDAQ:VXRT) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, BidAskClub reports.

Other equities analysts also recently issued reports about the stock. B. Riley reiterated a “buy” rating and issued a $22.00 price objective on shares of Vaxart in a report on Friday, August 7th. Zacks Investment Research downgraded shares of Vaxart from a “hold” rating to a “sell” rating in a report on Friday, September 11th. HC Wainwright upped their price objective on shares of Vaxart from $7.00 to $17.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Finally, ValuEngine downgraded shares of Vaxart from a “buy” rating to a “hold” rating in a report on Monday, June 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $13.42.

Shares of VXRT opened at $8.22 on Friday. The company has a market cap of $897.64 million, a price-to-earnings ratio of -13.93 and a beta of -0.04. Vaxart has a 1-year low of $0.25 and a 1-year high of $17.49. The company’s fifty day simple moving average is $7.61 and its 200 day simple moving average is $5.13. The company has a current ratio of 3.98, a quick ratio of 3.98 and a debt-to-equity ratio of 0.03.

Vaxart (NASDAQ:VXRT) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.06). The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $1.90 million. Vaxart had a negative return on equity of 84.90% and a negative net margin of 281.50%. As a group, research analysts forecast that Vaxart will post -0.35 earnings per share for the current year.

In related news, Director Armistice Capital, Llc sold 9,385,386 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $8.29, for a total value of $77,804,849.94. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 36.70% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. acquired a new position in shares of Vaxart in the second quarter valued at about $35,000. PNC Financial Services Group Inc. grew its stake in shares of Vaxart by 39.9% in the second quarter. PNC Financial Services Group Inc. now owns 4,451 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 1,270 shares in the last quarter. Bank of Montreal Can acquired a new position in shares of Vaxart in the second quarter valued at about $63,000. Rockefeller Capital Management L.P. bought a new stake in Vaxart during the second quarter worth about $75,000. Finally, Strs Ohio bought a new stake in Vaxart during the second quarter worth about $100,000. Institutional investors and hedge funds own 17.90% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.

Recommended Story: Bull Market

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.